CG Oncology

The biotech company is developing oncolytic immunotherapy for bladder cancer.

The Company is evaluating crestimogen as monotherapy in its ongoing Phase 3 study in high-risk patients not responding to BCG NMIBC. If successful, the trial could serve as the basis for a biologics license application to the Food and Drug Administration.

_____________________________

The number of employees:

40-61

_____________________________

Headquarters:

400 Spectrum Center Drive, Suite 2040 Irvine, CA 92618, USA